Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir-Reference-Cited by-同舟云学术

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

Published:2013-04 Issue:4 Volume:58 Page:646-654
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Karino Yoshiyasu,Toyota Joji,Ikeda Kenji,Suzuki Fumitaka,Chayama Kazuaki,Kawakami Yoshiiku,Ishikawa Hiroki,Watanabe Hideaki,Hernandez Dennis,Yu Fei,McPhee Fiona,Kumada Hiromitsu

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Hepatology

Reference25 articles.

1. Telaprevir for previously untreated chronic HCV infection;Jacobson;N Engl J Med,2011

2. Boceprevir for untreated chronic HCV genotype 1 infection;Poordad;N Engl J Med,2011

3. An update on treatment of genotype 1 chronic HCV infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases;Ghany;Hepatology,2011

4. Merck. VICTRELIS™ (boceprevir) [package insert]; 2012.

5. Vertex Pharmaceuticals. INCIVEK™ (telaprevir) [package insert]; 2012.

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study;Medicina;2023-08-08

2. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

3. The role of IFNL4 in liver inflammation and progression of fibrosis;Genes & Immunity;2022-05-18

4. Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B;Egyptian Liver Journal;2022-01-31

5. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03